Skip to content

The Spraino Pilot Trial

A Randomized Pilot Trial to Evaluate the Preliminary Effect and Safety of Using Spraino® to Prevent Lateral Ankle Sprains in Indoor Sports (The Spraino Pilot Trial)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03311490
Enrollment
510
Registered
2017-10-17
Start date
2017-10-19
Completion date
2018-10-05
Last updated
2019-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Athletes With Previous Lateral Ankle Sprain(s)

Keywords

Ankle Sprain, Prophylaxis, Indoor Sports, Ligamentous sprain, Prevention

Brief summary

This pilot study will establish the preliminary effect and safety of using Spraino® to prevent lateral ankle sprains amongst athletes competing in indoor sports at sub-elite level, with a one-year follow-up. All recruited participants will have a history of lateral ankle sprain in the preceding 24 months prior to the initiation of the trial. Half of the included participants will receive Spraino® to prevent lateral ankle sprains (intervention group). The other half will receive no intervention (do-as-usual control group). Both groups will be permitted to continue or initiate any usual care of their choice, except Spraino® in the control group. Short Message Services (SMS) will be used for registration of injury and exposure.

Detailed description

The purpose of this exploratory trial (named The Spraino Pilot Trial) is to establish the preliminary effect and safety of using Spraino® to prevent lateral ankle sprains amongst athletes competing in indoor sports at sub-elite level (handball, basketball, floorball and badminton) when compared to a do-as-usual control group. It is a randomized controlled pilot trial (Pilot-RCT) with a two-group parallel design and blinded outcome assessment. The trial will include prospective injury and exposure registration using a Short Message Services-system (SMS-Track) throughout a 52-week follow-up period (one calendar year). It is anticipated that 500 participants, which approximates to 250 in each group, will be enrolled in the trial. The enrollment process will cease when at least 250 participants have been allocated to the intervention group. Only athletes participating in indoor sports with a history of a lateral ankle sprain in the preceding 24 months are eligible for inclusion in the trial. The participants will be randomized (1:1 allocation ratio) using numbered lots. The randomization process will ensure stratification for gender, sports discipline and level of play. A full trial protocol, based on the SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials (Chan et al., 2013) and the PREPARE Trial guide (Bandholm et al., 2017), will be published and made publicly available. The trial report will adhere to the CONSORT 2010 statement, using the extension for randomized pilot and feasibility trials. Being an exploratory pilot trial, the study is designed with a flat outcome structure with multiple evenly valued outcome measures. Thus, no primary and secondary outcome measure hierarchy exists.

Interventions

DEVICESpraino

Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period.

Sponsors

Copenhagen University Hospital, Hvidovre
CollaboratorOTHER
Aalborg University
CollaboratorOTHER
Metropolitan University College
CollaboratorOTHER
The Copenhagen Center for Health Technology (CACHET)
CollaboratorUNKNOWN
Spraino
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Participant is ≥ 18 years old at commencement of trial. * Participant can read, speak and understand Danish. * Participant can receive and reply to texts on a cell phone using Short Message Services (SMS). * Participant performs indoor sports (Handball, basketball, floorball orbadminton) in a sub-elite level team with ≥ 2 weekly practice sessions. * Participant has incurred ≥ 1 lateral ankle sprain injury in the preceding 24 months. * Participant has returned to play at commencement of the trial.

Design outcomes

Primary

MeasureTime frameDescription
Lateral ankle sprains52 weeksRate of lateral ankle sprains (continuous) The incidence rate is defined as the number of lateral ankle sprains per 1000 hours of exposure.
First-time non-contact lateral ankle sprains52 weeksRate of first-time non-contact lateral ankle sprains (continuous) The incidence rate is defined as the number of first-time non-contact lateral ankle sprains per 1000 hours of exposure.
Time-loss due to first-time non-contact lateral ankle sprains52 weeksTime-loss (in number of weeks) due to first-time non-contact lateral ankle sprains per athlete (continuous)
Time-loss due to recurrent lateral ankle sprains52 weeksTime-loss (in number of weeks) due to recurrent lateral ankle sprains per athlete (continuous)
Severe first-time non-contact lateral ankle sprains52 weeksRate of severe first-time non-contact lateral ankle sprains (continuous) The incidence rate is defined as the number of severe first-time non-contact lateral ankle sprains (≥ 3 weeks with time-loss) per 1000 hours of exposure.
Recurrent non-contact lateral ankle sprains52 weeksRate of recurrent non-contact lateral ankle sprains (continuous) The incidence rate is defined as the number of recurrent non-contact lateral ankle sprains per 1000 hours of exposure.
Time-loss due to recurrent non-contact lateral ankle sprains52 weeksTime-loss (in number of weeks) due to recurrent non-contact lateral ankle sprains per athlete (continuous)
Severe recurrent non-contact lateral ankle sprains52 weeksRate of severe recurrent non-contact lateral ankle sprains (continuous) The incidence rate is defined as the number of severe recurrent non-contact lateral ankle sprains (≥ 3 weeks with time-loss) per 1000 hours of exposure.
First-time lateral ankle sprains52 weeksRate of first-time lateral ankle sprains (continuous) The incidence rate is defined as the summation of both contact and non-contact first-time lateral ankle sprains per 1000 hours of exposure.
Time-loss due to first-time lateral ankle sprains52 weeksTime-loss (in number of weeks) due to first-time lateral ankle sprains per athlete (continuous)
Severe first-time lateral ankle sprains52 weeksRate of severe first-time lateral ankle sprains (continuous) The incidence rate is defined as the number of severe first-time lateral ankle sprains (≥ 3 weeks with time-loss) per 1000 hours of exposure.
Recurrent lateral ankle sprains52 weeksRate of recurrent lateral ankle sprains (continuous) The incidence rate is defined as the summation of both contact and non-contact recurrent lateral ankle sprains per 1000 hours of exposure.
Severe recurrent lateral ankle sprains52 weeksRate of severe recurrent lateral ankle sprains (continuous) The incidence rate is defined as the number of severe recurrent lateral ankle sprains (≥ 3 weeks with time-loss) per 1000 hours of exposure.

Other

MeasureTime frameDescription
Adverse effects from using Spraino®52 weeksReports of adverse events in the intervention group (binary) All adverse events will be registered while the participants are enrolled in the trial. Adverse events will be reported as type and number of events. The included participants will be encouraged to report any adverse events related to the use of Spraino® to the trial hotline.
Fear of re-injury52 weeksFear of lateral ankle sprain re-injury (continuous) Change in fear of re-injury from pre- to post-trial intervention period. Fear of re-injury is scored on a numeric rating scale from 0 - 100 (0 = Extremely fear full, 100 = No fear at all)
Ankle pain52 weeksAnkle pain (continuous) Change in ankle pain from pre- to post-trial intervention period. Ankle pain is scored on a numeric rating scale from 0 - 10 (0 = No pain at all, 10 = Extremely painful)

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026